HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
With these encouraging data, we are busy finalizing plans for the randomized trial expected to begin next year,” said Joern Aldag, Chief Executive Officer at HOOKIPA Pharma.
- With these encouraging data, we are busy finalizing plans for the randomized trial expected to begin next year,” said Joern Aldag, Chief Executive Officer at HOOKIPA Pharma.
- Enrollment continued in the ongoing Phase 1/2 study ( NCT05553639 ) of HB-300 for the treatment of advanced prostate cancer.
- HB-300 is an arenaviral immunotherapy that targets two well-defined self-antigens of prostate cancer, prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA).
- The decrease was primarily attributable to cash used in operating activities, partly offset by funds resulting from the follow-on financing in June 2023.